Wegovy vs Ozempic. Same molecule, different label.
Wegovy vs Ozempic — both are semaglutide. The FDA-label split, dose ceilings, insurance implications, and which fits weight management.
Nothing about the drug — everything about the label. Wegovy and Ozempic are both semaglutide, the same GLP-1 receptor agonist from the same manufacturer. Ozempic is FDA-approved for type 2 diabetes; Wegovy is FDA-approved for chronic weight management, with a higher maximum dose (2.4 mg weekly versus Ozempic's 2.0 mg). The label split drives the real-world differences: what insurance covers, what dose you can reach, and which prescription is on-label for weight loss.
Why one drug wears two names.
Semaglutide was approved for type 2 diabetes in 2017 under the brand name Ozempic. After trials showed sustained weight reduction in non-diabetic patients with obesity or weight-related comorbidities, the manufacturer ran a separate approval pathway for the weight-management indication — and that label, approved in 2021, is Wegovy. Mounjaro and Zepbound split the same way for tirzepatide.
The chemistry inside the pen is identical. What differs is the FDA-approved indication, the labeled dose ladder, and the maximum dose: Wegovy titrates to 2.4 mg weekly, while Ozempic's label tops out at 2.0 mg. The weight-management trials were run at the higher dose, which is why Wegovy's label exists at all.
Patients sometimes arrive convinced they're different drugs — usually because insurance treats them so differently. They aren't. The honest framing is: this is semaglutide, and the name on the box reflects how the FDA approved its use, not the molecule.
Ozempic vs Wegovy, at a glance.
Both columns describe semaglutide. Cost figures are typical Los Angeles market ranges, not our pricing — our program pricing is discussed at consultation.
| Ozempic | Wegovy | |
|---|---|---|
| Molecule | Semaglutide | Semaglutide |
| FDA-approved indication | Type 2 diabetes (2017) | Chronic weight management (2021) |
| Labeled maximum dose | 2.0 mg weekly | 2.4 mg weekly |
| Dose ladder | 0.25 → 0.5 → 1.0 → 2.0 mg | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg |
| Insurance handling | Often covered for T2D · rarely for weight loss alone | Covered only when the plan includes GLP-1 weight management · plan-dependent |
| Use for weight loss | Off-label without a diabetes diagnosis | On-label for BMI ≥ 30, or ≥ 27 with a comorbidity |
| Typical LA cash-pay range | $650 – $1,000 per month | $650 – $1,300 per month |
What the label means for coverage and dose.
Insurance is where the label split bites. Plans that cover Ozempic typically do so for a documented type 2 diabetes diagnosis — prescribing it off-label for weight loss usually means cash pay. Wegovy coverage exists, but only on plans that include GLP-1 weight-management benefits, and those remain inconsistent plan to plan. The same molecule can cost a patient $25 a month or $1,000 a month depending entirely on which label their plan recognizes.
The dose ceiling matters less than patients expect. Many do their best work at intermediate doses — 1.0 or 1.7 mg — and never need Wegovy's 2.4 mg maximum. We titrate to effect, not to label maximum, which means the practical difference between the two labels is often smaller than the paper difference.
Supply has historically run tight on both brands, and compounded semaglutide exists as a lower-cost alternative with meaningfully different sourcing and regulatory considerations — the Ozempic cost guide maps the Los Angeles ranges for both. We use FDA-approved branded product unless there's a specific reason to discuss alternatives, and when we do, the tradeoffs are named plainly.
How the decision actually goes.
| Type 2 diabetes, weight secondary | Ozempic is the on-label tool, and coverage is typically workable. Weight reduction arrives as a documented secondary effect. Coordination with your prescribing physician or endocrinologist matters more than the brand question. |
|---|---|
| Weight management, no diabetes | Wegovy is the on-label choice — the weight-management indication and the 2.4 mg ceiling were built for exactly this case. Whether your plan covers it is a separate question we help you answer before committing to a supervised program. |
| Coverage-driven cases | In practice, access often dictates the brand. A patient whose plan covers one and not the other usually starts with what's covered. The molecule is the same; we don't treat the brand decision as clinically precious when the dose ladder overlaps. |
Supervised by Dr. Charles Peterson, board-certified physician with nearly a decade in aesthetic medicine.
Questions we get.
Are Wegovy and Ozempic interchangeable?
Pharmacologically they're the same molecule — semaglutide — at overlapping doses. Practically, no: the FDA labels, maximum doses, and insurance pathways differ, and pharmacies dispense them as separate products. Switching between them is a paperwork and coverage question, not a chemistry one.
Can I take Ozempic for weight loss without diabetes?
It happens widely, as off-label prescribing — which is legal and sometimes reasonable, but typically means no insurance coverage and a higher bar for clinical justification. With Wegovy available on-label for weight management, we default to the on-label path when access allows.
Which will my insurance cover?
Plan-dependent. Ozempic is commonly covered for type 2 diabetes and rarely for weight loss alone. Wegovy coverage depends on whether your plan includes GLP-1 weight-management benefits. We help you check before you commit — coverage shouldn't be a surprise at the pharmacy counter.
Why is Wegovy approved for weight loss and Ozempic isn't?
Approval follows trials. The weight-management trials (the STEP program) were run under the Wegovy label at doses up to 2.4 mg weekly, so that label carries the indication. Ozempic's trials were diabetes trials. Same molecule, different evidence packages submitted to the FDA.
Does Wegovy work better because the dose is higher?
At the maximum dose, trial-average weight reduction is somewhat greater than at Ozempic's 2.0 mg ceiling. But many patients respond well below either maximum, and we titrate to effect. The 2.4 mg ceiling matters mainly for patients who need the headroom.
Continue.
GLP-1 mechanism, on-label vs off-label use, candidacy, side-effect management, what happens when you stop.
Semaglutide vs tirzepatide — mechanism, trial weight-loss percentages, side-effect profiles, cost, and how we choose between them.
What Ozempic costs — branded vs compounded semaglutide market ranges, insurance and coupon realities, and how program pricing works.
Dosing schedule, week-by-week expectations, side-effect timeline, food strategies during titration, the Wegovy vs Ozempic distinction.